Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Amylyx class action Relyvrio
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 18.0¢ | $157.8K | 864.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 192000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 73740 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.5¢ |
Change
0.005 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 19.0¢ | 18.0¢ | 248618 | ||
| Last updated 15.45pm 30/05/2024 ? | |||||
| PAA (ASX) Chart |